Bruxelles

• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending
  2024-519655-28-00 5 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma Recruiting
  2025-521785-10-00 5 2026-03-04 Glioblastoma
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• A study to test the safety and efficacy of EP102 in patients with advanced solid tumours Recruiting
  2025-521305-40-00 1 2025-07-22 Participants with Advanced Solid Tumors
• Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting
  2023-508153-12-00 5 2024-03-26 Hospital-acquired pneumonia
• Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI … Recruiting
  2024-514693-47-01 11 2025-10-28 EGFR mutated locally advanced or metastatic non-small cell lung cancer
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infection … Recruiting
  2024-514358-56-00 6 2024-06-19 Patients presenting recurrent orofacial herpes infections (6 or more e
• Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infecti … Recruiting
  2024-514222-24-00 6 2024-06-04 Epstein-Barr Virus infection
• Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LVERU®JUNIOR and 2LVERU® on the treatment of warts. EVAsION … Recruiting
  2024-514476-40-00 11 2024-06-03 Non genital warts infection
• Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LPAPI® on the clearance of high-risk oncogenic HPV genital i … Recruiting
  2024-513969-39-00 6 2024-05-09 Human Papillomavirus infection
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusion Ended recruitment
  2022-502878-16-00 5 2025-01-23 Acute ischemic strokes with incomplete reperfusion
• PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment
  2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
• A pilot open label phase I trial to evaluate the safety and the tolerability of a combination of two HIV-1 inducers in HIV+ sub-type B patie … Ended recruitment
  2024-518141-13-00 3 2022-12-05 HIV
• Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, … Ended recruitment
  2024-516847-23-00 4 2019-08-27 ER-positive and HER2-negative metastatic or locally advanced breast ca
• PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient … Ended recruitment
  2024-518741-21-00 4 2014-12-23 colon cancer
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Public title :A Phase 1b/2a trial to evaluate Invobenitug also known as Procizumab (PCZ; AK1967) in critical cardiovascular care. Halted
  2024-518450-16-00 9 2025-06-13 Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of
• Study Drug vs Placebo as an “add on” treatment for Severe Community-Acquired Pneumonia. Ended
  2023-505985-28-01 4 2024-03-04 Severe Community-Acquired Pneumonia
• A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors Ended
  2024-518529-14-00 7 2021-02-26 Metastatic/advanced soft tissue sarcoma (STS), Merkel cell carcinoma (

Showing 1–23 of 23 trials